SOE deadline: Q&A Session with our experts

Register & submit your questions →

Oral intake of curcumin with piperine reduce the morbidity and mortality in COVID-19 patients: a randomized controlled trial

This double-blind, randomized and controlled trial aimed to determine the effects of curcumin administered with piperine (to optimize absorption) on symptoms of patients with COVID-19 in addition to conventional treatment. Subjects received curcumin (525 mg) with piperine (2.5 mg) in tablet form (intervention group) or probiotics (control group) twice a day. Results revealed that curcumin and piperine treatment showed early symptomatic recovery (fever, cough, sore throat, and breathlessness), less deterioration, fewer red flag signs, better ability to maintain oxygen saturation above 94% on room air, and better clinical outcomes compared to control group. Furthermore, curcumin and piperine treatment appeared to reduce the duration of hospitalization and resulted in fewer death in the intervention group. Authors concluded that curcumin with piperine as an adjuvant therapy could substantially reduce morbidity and mortality in COVID-19 patients and could be therefore a safe and natural therapeutic option to prevent post-COVID thromboembolic events.

Pawar KS, Mastud RN, Pawar SK, Pawar SS, Bhoite RR, Bhoite RR, Kulkarni MV, Deshpande AR. Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial. Front Pharmacol. 2021 May 28;12:669362. doi: 10.3389/fphar.2021.669362. PMID: 34122090; PMCID: PMC8193734.

Photo by FOODISM360 on Unsplash